Year archive

Alvotech Holdings S.A — 2024 filings

All 214 regulatory filings released by Alvotech Holdings S.A (ALVO) in 2024, sourced directly from the official regulator.

214 Filings

2024 Period

2024 filings (214)

Filing	Released	Lang
pdf5009312744798760428 (1) Director's Dealing	2024-12-30	English
FORM 6-K Regulatory Filings	2024-12-23	English
Hlutabréf Alvotech tekin inn í Líftæknivístölu Nasdaq Regulatory Filings	2024-12-23	Icelandic
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 Regulatory Filings	2024-12-23	English
Managers Transaction-CSSF Form - ATP Holdings ehf 20241218.pdf Director's Dealing	2024-12-19	English
Viðskipti stjórnenda og tengdra aðila Director's Dealing	2024-12-19	English
Managers Transaction-CSSF Form - ATP Holdings ehf 20241218.pdf Director's Dealing	2024-12-19	English
Transactions of Managers and Closely Associated Persons Director's Dealing	2024-12-19	English
FORM 6-K Regulatory Filings	2024-11-13	English
Presentation Q3 2024.pdf Investor Presentation	2024-11-13	English
Alvotech birtir fjárhagsuppgjör fyrir fyrstu níu mánuði ársins 2024 Earnings Release 9M 2024	2024-11-13	Icelandic
Presentation Q3 2024.pdf Investor Presentation	2024-11-13	English
Alvotech Reports Financial Results for the First Nine Months of 2024 Earnings Release 9M 2024	2024-11-13	English
Alvotech fundar með fjárfestum á heilbrigðisráðstefnum Citi og Evercore fjárfestingabankanna dagana 4. og 5. desember 2024 Investor Presentation	2024-11-07	Icelandic
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 Regulatory Filings	2024-11-07	English
SC 13G/A Major Shareholding Notification	2024-11-06	English
FORM 6-K Regulatory Filings	2024-11-04	English
Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir AVT05, fyrirhugaða líftæknilyfjahliðstæðu við Simponi (golimumab) Regulatory Filings	2024-11-04	Icelandic
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) Regulatory Filings	2024-11-04	English
Alvotech mun birta uppgjör fyrstu níu mánaða ársins miðvikudaginn 13. nóvember nk. og streyma uppgjörsfundi fimmtudaginn 14. nóvember nk. kl. 13:00 að íslenskum tíma Report Publication Announcement	2024-10-30	Icelandic
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET Report Publication Announcement	2024-10-30	English
Alvotech to Report Financial Result.. Report Publication Announcement	2024-10-30	Icelandic
Alvotech to Report Financial Result.. Report Publication Announcement	2024-10-30	English
Alvotech fundar með fjárfestum og heldur kynningu á heilbrigðisráðstefnu Jefferies í London 19.-20. nóvember 2024 Regulatory Filings	2024-10-25	Icelandic
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19-20, 2024 Regulatory Filings	2024-10-25	English
FORM 6-K Regulatory Filings	2024-10-22	English
Alvotech veitt aukið markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn), líftæknilyfjahliðstæðu við Stelara, til meðferðar sjúkdóma í meltingarvegi Regulatory Filings	2024-10-22	Icelandic
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (us Regulatory Filings	2024-10-22	English
FORM 6-K Regulatory Filings	2024-10-10	English
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® Regulatory Filings	2024-10-10	Icelandic
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® Regulatory Filings	2024-10-10	English
Unaudited Consolidated Financial Statements Q2 2024 Interim / Quarterly Report H1 2024	2024-10-01	English
Alvotech hefur klíníska rannsókn á AVT16, fyrirhugaðri líftæknilyfjahliðstæðu við Entyvio Regulatory Filings	2024-09-25	Icelandic
Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® Regulatory Filings	2024-09-25	English
Regulatory Filings 2024 Regulatory Filings	2024-08-30	English
Registration Statement Declared Effective Regulatory Filings	2024-08-29	Icelandic
Registration Statement Declared Effective Regulatory Filings	2024-08-29	English
Regulatory Filings 2024 Regulatory Filings	2024-08-29	English
Regulatory Filings 2024 Regulatory Filings	2024-08-27	English
Filing of a Request with the SEC Regulatory Filings	2024-08-27	Icelandic
Filing of a Request with the SEC Report Publication Announcement	2024-08-27	English
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference Report Publication Announcement	2024-08-26	Icelandic
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference Regulatory Filings	2024-08-26	English
Regulatory Filings 2024 Regulatory Filings	2024-08-23	English
Filing of a Preliminary Prospectus with the SEC Capital/Financing Update	2024-08-22	English
Filing of a Preliminary Prospectus with the SEC Capital/Financing Update	2024-08-22	English
Regulatory Filings 2024 Regulatory Filings	2024-08-21	English
6-K Regulatory Filings	2024-08-15	English
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 Interim / Quarterly Report H1 2024	2024-08-15	English
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 Management Reports	2024-08-15	English
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 Earnings Release H1 2024	2024-08-15	English
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 Interim / Quarterly Report H1 2024	2024-08-15	English
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 Earnings Release H1 2024	2024-08-15	English
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 Management Reports	2024-08-15	English
FORM 6-K Regulatory Filings	2024-08-15	English
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) Regulatory Filings	2024-08-15	Icelandic
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) Regulatory Filings	2024-08-15	English
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET Report Publication Announcement	2024-08-01	Icelandic
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET Report Publication Announcement	2024-08-01	English
FORM 6-K Regulatory Filings	2024-07-22	English
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe Regulatory Filings	2024-07-22	Icelandic
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe Regulatory Filings	2024-07-22	English
FORM 6-K Regulatory Filings	2024-07-11	English
Alvotech lýkur við endurfjármögnun skulda með lægri fjármagnskostnaði og lengri lánstíma Capital/Financing Update	2024-07-11	Icelandic
Alvotech Announces Closing of Private Debt Financing Capital/Financing Update	2024-07-11	English
Alvotech Announces Closing of Private Debt Financing Capital/Financing Update	2024-07-11	Icelandic
Alvotech Announces Closing of Private Debt Financing Capital/Financing Update	2024-07-11	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-07-03	English
VOTING_RIGHTS_CAPITAL_TOTAL_2024-03 (20240703) Declaration of Voting Results & Voting Rights Announcements	2024-07-03	English
Major Shareholder Announcement Major Shareholding Notification	2024-07-03	English
Major Shareholder Announcement Major Shareholding Notification	2024-07-03	English
Transactions of Managers and Closely Associated Persons Director's Dealing	2024-07-03	English
Transactions of Managers and Closely Associated Persons Director's Dealing	2024-07-03	English
Major Holdings Notification (Annex A) ATP Holdings ehf (20240702) Major Shareholding Notification	2024-07-03	English
Managers Transaction Notification ATP Holdings ehf (20240702) Director's Dealing	2024-07-03	English
FORM 6-K Regulatory Filings	2024-07-02	English
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® Regulatory Filings	2024-07-02	Icelandic
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® Regulatory Filings	2024-07-02	English
FORM 6-K Regulatory Filings	2024-07-02	English
Alvotech gefur út nýja hluti í skiptum fyrir breytileg skuldabréf Share Issue/Capital Change	2024-07-01	Icelandic
Alvotech Issues New Shares to Holders of Convertible Bonds Share Issue/Capital Change	2024-07-01	English
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024 Earnings Release Q2 2024	2024-07-01	Icelandic
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024 Earnings Release Q2 2024	2024-07-01	English
Regulatory Filings 2024 Regulatory Filings	2024-07-01	English
FORM 6-K Regulatory Filings	2024-07-01	English
Regulatory Filings 2024 Regulatory Filings	2024-06-26	English
Alvotech - Request for Withdrawal of Registration Statement.pdf Regulatory Filings	2024-06-26	English
Beiðni lögð inn til Verðbréfaeftirlits Bandaríkjanna um afturköllun skráningarlýsingar Regulatory Filings	2024-06-26	Icelandic
Alvotech - Request for Withdrawal of Registration Statement.pdf Regulatory Filings	2024-06-26	English
Text of Request Filed With the U.S. Securities and Exchange Commission Share Issue/Capital Change	2024-06-26	English
Alvotech Receives Conversion Notices for Majority of Convertible Bonds Share Issue/Capital Change	2024-06-26	Icelandic
Alvotech Receives Conversion Notices for Majority of Convertible Bonds Share Issue/Capital Change	2024-06-26	English
Transactions of Managers and Closely Associated Persons Director's Dealing	2024-06-26	English
Transactions of Managers and Closely Associated Persons Director's Dealing	2024-06-26	English
FORM 6-K Regulatory Filings	2024-06-26	English
Alvotech - Managers' Transaction Notification - Richard Davies (Arendt 20240625) Director's Dealing	2024-06-25	English
FORM 6-K Regulatory Filings	2024-06-18	English
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe Regulatory Filings	2024-06-18	Icelandic
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe M&A Activity	2024-06-18	English
Filing of Form 6-K with the U.S. Securities and Exchange Commission Capital/Financing Update	2024-06-14	English
Filing of Form 6-K with the U.S. Securities and Exchange Commission Regulatory Filings	2024-06-14	English
Filing of Form 6-K with the U.S. Securities and Exchange Commission Capital/Financing Update	2024-06-14	English
Filing of Form 6-K with the U.S. Securities and Exchange Commission Regulatory Filings	2024-06-14	English
Filing of Form 6-K with the U.S. Securities and Exchange Commission Regulatory Filings	2024-06-14	English
Filing of Form 6-K with the U.S. Securities and Exchange Commission Share Issue/Capital Change	2024-06-14	English
Filing of Form 6-K with the U.S. Securities and Exchange Commission Regulatory Filings	2024-06-14	English
Filing of Form 6-K with the U.S. Securities and Exchange Commission Regulatory Filings	2024-06-14	English
Filing of Form 6-K with the U.S. Securities and Exchange Commission Share Issue/Capital Change	2024-06-14	English
Regulatory Filings 2024 Regulatory Filings	2024-06-14	English
Regulatory Filings 2024 Regulatory Filings	2024-06-14	English
FORM 6-K Regulatory Filings	2024-06-11	English
FORM 6-K Regulatory Filings	2024-06-11	English
Alvotech and STADA add to Strategic Alliance through Denosumab Partnership M&A Activity	2024-06-11	Icelandic
Alvotech and STADA add to Strategic Alliance through Denosumab Partnership Regulatory Filings	2024-06-11	English
Granting of Stock Options and Restricted Share Units Director's Dealing	2024-06-07	English
Granting of Stock Options and Restricted Share Units Director's Dealing	2024-06-07	English
Main Results of Annual and Extraordinary General Meeting AGM Information	2024-06-07	English
Main Results of Annual and Extraordinary General Meeting AGM Information	2024-06-07	English
Alvotech - Managers' Transaction Notification - Linda McGoldrick Director's Dealing	2024-06-07	English
Alvotech - Managers' Transaction Notification - Richard Davies Director's Dealing	2024-06-07	English
Alvotech - Managers' Transaction Notification - Lisa Graver Director's Dealing	2024-06-07	English
Alvotech - Managers' Transaction Notification - Ann Merchant Director's Dealing	2024-06-07	English
0001171843-24-003336 Capital/Financing Update	2024-06-07	English
FORM 6-K Regulatory Filings	2024-06-07	English
Alvotech Announces Strategic Refinancing Agreement Capital/Financing Update	2024-06-07	English
Alvotech Announces Strategic Refinancing Agreement Capital/Financing Update	2024-06-07	Icelandic
Alvotech Announces Strategic Refinancing Agreement Capital/Financing Update	2024-06-07	English
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024 Investor Presentation	2024-05-29	Icelandic
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024 Investor Presentation	2024-05-29	English
Transactions of Managers and Closely Associated Persons Director's Dealing	2024-05-28	English
Transactions of Managers and Closely Associated Persons Director's Dealing	2024-05-28	English
Managers Transaction-eRIIS Form- ATP Holdings ehf. Director's Dealing	2024-05-28	English
FORM 6-K Regulatory Filings	2024-05-22	English
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update Earnings Release Q1 2024	2024-05-21	Icelandic
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update Earnings Release Q1 2024	2024-05-21	English
FORM 6-K Regulatory Filings	2024-05-21	English
FORM 6-K Regulatory Filings	2024-05-21	English
Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK Environmental & Social Information	2024-05-21	Icelandic
Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK M&A Activity	2024-05-21	English
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. M&A Activity	2024-05-21	Icelandic
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. Regulatory Filings	2024-05-21	English
Alvotech S.A. Annual General Meeting to be held June 7, 2024 AGM Information	2024-05-15	English
Alvotech S.A. Annual General Meeting to be held June 7, 2024 AGM Information	2024-05-15	English
ANNUAL_FINANCIAL_AUDIT_REPORTS_2024-05-14_18h27m48 Regulatory Filings	2024-05-15	English
222100DCZBOWV5DZ8372-2023-12-31-en Annual Report FY 2023	2024-05-13	English
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) Report Publication Announcement	2024-05-13	Icelandic
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) Report Publication Announcement	2024-05-13	English
Alvotech S.A. Audit report 31.12.2023 final_signed Annual Report FY 2023	2024-05-07	English
90d239f8-31cc-44e1-b5c5-364d0a889d63 Audit Report / Information FY 2023	2024-05-07	English
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 Regulatory Filings	2024-05-02	Icelandic
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 Regulatory Filings	2024-05-02	English
FORM 6-K Regulatory Filings	2024-04-30	English
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) Regulatory Filings	2024-04-30	Icelandic
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) Regulatory Filings	2024-04-30	English
FORM 6-K Regulatory Filings	2024-04-25	English
Alvotech kynnir jákvæða niðurstöðu rannsóknar á sjúklingum sem sýnir sömu klínísku virkni líftæknilyfjahliðstæðunnar AVT05 og Simponi® (golimumab) Regulatory Filings	2024-04-24	Icelandic
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) Regulatory Filings	2024-04-24	English
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) Regulatory Filings	2024-04-24	Icelandic
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) Regulatory Filings	2024-04-24	English
FORM 6-K Regulatory Filings	2024-04-19	English
Alvotech gerir sölusamning í Bandaríkjunum um fyrstu líftæknilyfjahliðstæðuna í háum styrk með útskiptanleika við Humira Regulatory Filings	2024-04-19	Icelandic
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) Regulatory Filings	2024-04-19	English
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) Regulatory Filings	2024-04-19	Icelandic
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) Regulatory Filings	2024-04-19	English
FORM 6-K Regulatory Filings	2024-04-17	English
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) Regulatory Filings	2024-04-16	Icelandic
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) Regulatory Filings	2024-04-16	English
Alvotech Manco ehf. - Notification of Major Holdings (20240403) Major Shareholding Notification	2024-04-05	English
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 Report Publication Announcement	2024-04-03	Icelandic
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 Report Publication Announcement	2024-04-03	English
Alvotech - Total Voting Rights Notification (20240326) Declaration of Voting Results & Voting Rights Announcements	2024-03-28	English
Managers Transaction Notification J Morales 20240320.pdf Director's Dealing	2024-03-22	English
Transaction of Managers and Closely Associated Persons Director's Dealing	2024-03-22	English
FORM 6-K Regulatory Filings	2024-03-22	English
Managers' Transaction Notification J Morales 20240320 Director's Dealing	2024-03-22	English
Transaction of Managers and Closely Associated Persons Director's Dealing	2024-03-22	English
Alvotech Announces Increase in Number of Own Shares Share Issue/Capital Change	2024-03-22	Icelandic
Alvotech Announces Increase in Number of Own Shares Share Issue/Capital Change	2024-03-22	English
20-F Annual Report FY 2023	2024-03-20	English
FORM 6-K Regulatory Filings	2024-03-20	English
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update Annual Report FY 2023	2024-03-20	English
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update Annual Report FY 2023	2024-03-20	English
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update Annual Report FY 2023	2024-03-20	English
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update Annual Report FY 2023	2024-03-20	English
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET Report Publication Announcement	2024-03-05	Icelandic
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET Report Publication Announcement	2024-03-05	English
FORM 6-K Regulatory Filings	2024-03-01	English
Alvotech Appoints Interim Chief Quality Officer Board/Management Information	2024-02-29	Icelandic
Alvotech Appoints Interim Chief Quality Officer Board/Management Information	2024-02-29	English
FORM 6-K Regulatory Filings	2024-02-26	English
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share Share Issue/Capital Change	2024-02-26	Icelandic
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share Capital/Financing Update	2024-02-26	English
FORM 6-K Regulatory Filings	2024-02-24	English
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® Regulatory Filings	2024-02-24	Icelandic
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® Regulatory Filings	2024-02-24	English
FORM 6-K Regulatory Filings	2024-02-15	English
Alvotech tilkynnir hvenær sala á AVT04, líftæknilyfjahliðstæðu við Stelara, getur hafist á alþjóðlegum mörkuðum Regulatory Filings	2024-02-15	Icelandic
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab) Regulatory Filings	2024-02-15	English
SC 13G/A Major Shareholding Notification	2024-02-14	English
FORM 6-K Regulatory Filings	2024-01-29	English
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® Regulatory Filings	2024-01-29	Icelandic
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® Regulatory Filings	2024-01-29	English
Transactions of Managers and Closely Associated Persons Director's Dealing	2024-01-24	English
Transactions of Managers and Closely Associated Persons Director's Dealing	2024-01-24	English
Managers Transaction-CSSF Form - ATP Holdings ehf 20230123 Director's Dealing	2024-01-24	English
FORM 6-K Regulatory Filings	2024-01-19	English
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 Legal Proceedings Report	2024-01-19	Icelandic
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 Regulatory Filings	2024-01-19	English
FORM 6-K Regulatory Filings	2024-01-10	English
STADA and Alvotech Secure Approval for Uzpruvo, Europe's First Ustekinumab Biosimilar to Stelara Regulatory Filings	2024-01-10	Icelandic
STADA and Alvotech Secure Approval for Uzpruvo, Europe's First Ustekinumab Biosimilar to Stelara Regulatory Filings	2024-01-10	English
FORM 6-K Regulatory Filings	2024-01-03	English
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept) Regulatory Filings	2024-01-03	Icelandic
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept) Regulatory Filings	2024-01-03	English